about
Skeletal stem cells and their contribution to skeletal fragility: senescence and rejuvenationMeasuring the musculoskeletal aging phenotype.EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndromeRole of Phosphatidic Acid Phosphatase Domain Containing 2 in Squalestatin 1-Mediated Activation of the Constitutive Androstane Receptor in Primary Cultured Rat HepatocytesExamining the Relationships Between Bone Tissue Composition, Compositional Heterogeneity, and Fragility Fracture: A Matched Case-Controlled FTIRI Study.Bisphosphonate treatment and dental implants: A systematic reviewFracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review.Advances in Controlled Drug Delivery for Treatment of OsteoporosisOsteomacs and Bone Regeneration.Telementoring: a novel approach to reducing the osteoporosis treatment gap.Preliminary Study to Test the Feasibility of Sex Identification of Human (Homo sapiens) Bones Based on Differences in Elemental Profiles Determined by Handheld X-ray Fluorescence.Naringin enhances osteogenic differentiation through the activation of ERK signaling in human bone marrow mesenchymal stem cells.Degeneration of the osteocyte network in the C57BL/6 mouse model of aging.Hip fracture trends in the United States, 2002 to 2015.Random Electromyostimulation Promotes Osteogenesis and the Mechanical Properties of Rat Bones.Emerging anabolic agents in the treatment of osteoporosis.Effects of omega-3 fatty acids on bone turnover markers in postmenopausal women: systematic review and meta-analysis.Gastrodin protects MC3T3-E1 osteoblasts from dexamethasone-induced cellular dysfunction and promotes bone formation via induction of the NRF2 signaling pathway.Association of the insulin-like growth factor-1 single nucleotide polymorphisms rs35767, rs2288377, and rs5742612 with osteoporosis risk: A meta-analysis.Bone Health ECHO: telementoring to improve osteoporosis care.Bone Mineral Density, 25-OH Vitamin D and Inflammation in Patients with Psoriasis.Polymorphisms in key bone modulator cytokines genes influence bisphosphonates therapy in postmenopausal women.Oleanolic Acid Exerts Osteoprotective Effects and Modulates Vitamin D Metabolism.Heavy metals accumulation affects bone microarchitecture in osteoporotic patients.Changes in blood and urinary cadmium levels and bone mineral density according to osteoporosis medication in individuals with an increased cadmium body burden.The effect of atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (HMG-CoA), on the prevention of osteoporosis in ovariectomized rabbits.Metabolomic profiles associated with bone mineral density in US Caucasian womenPotassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot StudyNew and emerging concepts in the use of denosumab for the treatment of osteoporosis
P2860
Q26778170-973F0658-FF14-4E5D-8A47-C19E0C484539Q30251460-74420F7D-D52E-4E26-84D7-0C96B37548F8Q33731711-B6815FAA-3F81-4215-B09B-98CF979C5A63Q36618661-2F745822-1E67-4F57-AAAB-ECC2587EAC2FQ36889362-E54FBD73-4036-43F8-9A4A-33DE44DBB8F8Q37217791-39CFC66D-35C9-4FF5-A62D-DB1D08E0043BQ38692553-19963A52-8563-4A32-B7DC-C02D9D0CE8A8Q38778145-84A2659F-A877-4AA6-9B69-87374B1E98AAQ38922086-C936B03C-47A2-4CF1-88E7-6A613D62B885Q39396797-3051C539-F046-47C8-816C-B4FDAFF65FD2Q39579615-B35BDECA-8B1F-4341-B5E2-683FE195FA1EQ40048321-5C51DC12-065B-4F04-8B94-5D175013298EQ41881607-C44F575C-E3EB-4BE3-B4C2-A6BEEF5A1A95Q47135954-9C1780E2-D1AF-4BDF-9697-2990465A679DQ47241208-CD6DF57C-BF0E-436B-9E9C-E3E783EF0FA5Q47656086-48D41709-650E-44BE-9F66-D80296AB1102Q48012226-07176239-A10A-4E51-B049-2688A3CE9FC7Q48183681-D4D6CAE1-2DC2-4D4A-B096-4BF643F630DFQ49379739-3370E806-0FD8-4A70-AE33-86F10524203FQ49486582-B9E768C9-C5E0-4C8A-81F8-806631D983FCQ49782873-997E4CF0-50EA-4669-880A-A446B96CF8DAQ50932005-D1283CE7-891B-4468-A07E-56F0EC3FC1A7Q51129812-D5CBC426-DD14-426C-A993-62D60F9A6163Q51767979-4C10FE8D-8D8C-4A7E-92CA-2B25E6276042Q53060569-E151C004-CE2F-4D1F-B8EB-55D2B3858F97Q53113382-78CDD23A-1625-47D2-ABAF-4AD0FECD8C75Q53765744-04B5FE01-9A2A-4DA3-962D-F8C7DC2CFEA3Q57112162-F469C455-F165-4794-8A1C-37B765FA96CCQ57213305-9555EF9D-521D-4177-A551-4AC9E7BAD2E3Q58583955-F891B62F-696E-4A59-B5AB-75569FDE9E13
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The Pathophysiology and Treatment of Osteoporosis.
@en
type
label
The Pathophysiology and Treatment of Osteoporosis.
@en
prefLabel
The Pathophysiology and Treatment of Osteoporosis.
@en
P2093
P1476
The Pathophysiology and Treatment of Osteoporosis.
@en
P2093
Bart L Clarke
E Michael Lewiecki
Matthew T Drake
P304
P356
10.1016/J.CLINTHERA.2015.06.006
P577
2015-07-07T00:00:00Z